TMS and Attentional Bias in Functional Motor Disorder

Conversion Disorder Clinical Trial

Official title:

TMS and Attentional Bias in Functional Motor Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02102906
• Other study ID #: TMS
• Status: Completed
• Phase: N/A
• First received: March 31, 2014
• Last updated: February 8, 2016
• Start date: October 2014
• Est. completion date: November 2015

Study information

• Verified date: December 2014
• Source: University of Edinburgh
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Functional motor disorders, also called motor conversion disorder, are common reasons for attendance at neurology outpatient clinics. Patients with functional motor disorders are more common than patients with multiple sclerosis and have similar levels of disability but more psychological morbidity.

There is limited evidence for effective treatments in functional motor disorders. A small number of studies of transcranial magnetic stimulation (TMS), a painless method of cortical stimulation, have reported improvement in functional weakness after this treatment including in patients with symptoms of several years duration. The Investigators intend to trial TMS in a group of 40 patients with functional motor disorder, randomising patients to immediate or delayed treatment and therefore comparing a single session of TMS with routine clinical care. The Investigators will also ask patients to undergo tests of attentional focus in a cognitive neuroscience laboratory - these experiments will be analysed separately from TMS trial data.

Description:

A randomised non-blinded controlled study design will be used, with 3 months of treatment as usual as the control condition and a single session of TMS as the treatment condition.

40 patients with functional unilateral upper limb weakness will be recruited from neurology and neuropsychiatry clinics in Edinburgh and randomised to either immediate treatment or to 3 month delay during which they will receive routine clinical care. Randomisation will be performed using computerised random number generator by a person not involved with the study.

Patients randomised to delay will complete baseline measures of disability and motor function including SF36, modified Rankin score and study specific questionnaires, and will repeat these after 3 months. Patients undergoing immediate treatment will complete the same questionnaires immediately before and 3 months after treatment. All individuals receiving TMS treatment will undergo tests of grip strength and tapping frequency immediately before and after treatment.

The treatment and experiments involved will be as follows. Patients will attend the PPLS Cognitive Neuroscience Laboratory at George Square, University of Edinburgh for a single 2 hour session. During the first hour they will complete baseline symptom severity and disability questionnaires and will undertake a series of 3 experiments. Experiments involve participants sitting with their head on a chin-rest looking at either a computer screen or at lights projected onto their own hands, and for one experiment with a vibrating 'buzzer' taped to each hand. They will be asked to respond verbally in experiments which test their response to distracting attentional 'cues' either visual or vibrotactile. These experiments will take less than 1 hour. In anaylsis, performance will be compared between affected and unaffected sides (ie left hand and right hand), and will also be compared with performance of a group of 15 healthy control participants recruited from spouses or partners.

Patient participants will then receive treatment with 20 single pulses of TMS to the motor cortex at 120% motor threshold. These will cause visible and palpable 'jerks' of the affected limb. Between stimulations the researcher will offer verbal encouragement and ask the participant to move the affected limb if possible. Treatment will take less than 1 hour.

The primary outcome measures are patient-rated symptom severity and disability and simple statistical analysis will be used to compare outcome after 3 months of treatment as normal and 3 months after a single session of TMS treatment. Secondary outcome measures include grip strength and tapping frequency before and after treatment. Data will be analysed on an intention-to-treat basis. Data from attentional tests will be analysed separately.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: November 2015
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• clinical diagnosis, by a consultant neurologist, of functional motor disorder

• functional unilateral upper limb weakness present for 50% or more of the time

• age 18-75

• ability to give informed consent

Exclusion Criteria:

• difficulties in understanding spoken or written English

• history of epileptic seizures (non-epileptic seizures will not be an exclusion criteria)

• alcohol dependence

• severe co-morbid physical or psychiatric disorder

• factitious disorder

• patients unable to receive TMS because of metal implants such as pacemakers

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Conversion Disorder
• Disease
• Dissociative Disorders

Intervention

Procedure:
• Transcranial magnetic stimulation
Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.

Locations

Country	Name	City	State
United Kingdom	Department of Clinical Neurosciences, Western General Hospital	Edinburgh	Scotland
United Kingdom	Department of Psychology, University of Edinburgh	Edinburgh	Scotland

Sponsors (1)

Lead Sponsor	Collaborator
University of Edinburgh

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Attentional focus / distractibility	A short series of neurocognitive experiments based on a modified Posner test will examine for differences in attentional focus between affected and unaffected limbs and will also compare performance with a group of healthy controls recruited from spouses.	Tests performed during the 1-2 hours before treatment.	No
Primary	Patient-rated disability	SF36 score and Modified Rankin Score	An average of 3 months after day of attendance for TMS treatment.	No
Primary	Patient rated symptom severity	Assessed using a Likert scale.	An average of 3 months after day of attendance for TMS treatment	No
Secondary	Grip strength		Between 10 minutes and one hour before TMS treatment, and between 10 minutes and 1 hour after TMS treatment.	No
Secondary	Hand tapping frequency		Between 10 minutes and one hour before TMS treatment, and between 10 minutes and 1 hour after TMS treatment	No
Secondary	Patient rated treatment discomfort		Between 10 minutes and 1 hour after TMS treatment.	No